Previous close | 6.49 |
Open | 6.38 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 6.36 - 6.45 |
52-week range | 6.36 - 6.45 |
Volume | |
Avg. volume | N/A |
Market cap | 570.953M |
Beta (5Y monthly) | 1.22 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.71 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
VALNEVA Declaration of shares and voting rightsJanuary 31, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: February 3, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change
VALNEVA Declaration of shares and voting rightsStatus on December 31, 2022 (corrected data) and January 4, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: January 19, 2023 Erratum: status on December 31, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.